---
title: dFDA ROI Analysis
description: Return on investment analysis showing 463:1 central estimate with sensitivity scenarios
jupyter: dih-project-kernel
---

```{python}
#| echo: false
import sys
import os

# Quarto executes from project root (execute-dir: project in _quarto.yml)
appendix_path = os.path.join(os.getcwd(), 'brain', 'book', 'appendix')
if appendix_path not in sys.path:
    sys.path.insert(0, appendix_path)

from economic_parameters import *
```


## ROI Analysis

The return on investment for the dFDA Infrastructure is exceptionally high due to its nature as a leveraged, global software infrastructure. Unlike investments in single drugs or therapies, an investment in the dFDA Infrastructure creates systemic efficiencies that benefit the entire R&D ecosystem. The primary economic benefit is the drastic reduction in clinical trial operational costs, which can be redeployed to fund a greater volume and diversity of research.

### Methodology

1. **Compare Baseline to Future State**:

   - **Baseline**: [30–40 new drugs approved annually in the U.S.](https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2022), each costing [\$1 - \$2.5 billion](#data-sources-and-methodological-notes) on average for full development and approval. Total R&D spending (industry-wide) is on the order of [\$90 - \$100+ billion per year globally](#market-size-and-impact).
   - **Future State**: Potentially hundreds (even thousands) of continuous trials, each at a fraction of the cost. This could double or triple the number of new approvals/indications tested each year and expand to off-patent/unpatented therapies that are currently underexplored.

2. **Model Inputs**

   - **Upfront Cost (Core Platform Build):** Based on the ROM estimate of **~\$37.5 - \$46 Million** detailed in [Upfront (Capital) Expenditure](#upfront-capital-expenditure-initial-build-illustrative-30-months). For ROI calculations, a representative figure (e.g., `{python} format_millions(DFDA_ANNUAL_OPEX)`) will be used.
   - **Annual Operational Cost (Core Platform):** Based on the ROM estimate of **~\$11 - \$26.5 Million / year** detailed in [Annual Operational Costs](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month).
   - **Annual Broader Initiative Costs:** These can vary significantly, from near zero in optimistic scenarios to tens or hundreds of millions annually. The ROI analysis will consider scenarios, including a "Lean Ecosystem" that combines core platform operational costs with the **Medium Case annual broader initiative costs (~\$21.3 Million / year)** from [Scenario-Based ROM Estimates for Broader Initiative Costs](#scenario-based-rom-estimates-for-broader-initiative-costs).
     _(Note: The ROI analysis will primarily focus on these ROM-derived costs. Previous high-level conceptual estimates for a fully scaled, long-term global dFDA vision, which were significantly larger, are superseded by these more granular figures from the ['Costs of Building and Operating the Global Decentralized FDA ROM Estimate'](#costs-of-building-and-operating-the-global-decentralized-fda-rom-estimate) section for the purpose of this ROI calculation.)_

   - **Cost Reduction**: Up to 80× in the biggest, most efficient scenarios; conservative average ~50%–80% reduction in trial costs.
   - **Increased Throughput**: 2×–5× more trials and potentially many more candidates tested in parallel.
   - **Faster to Market**: Potentially 1–3 years shaved off a typical 7–10 year development cycle, yielding earlier revenue generation and extended effective patent life for sponsors.

### Simplified ROI Scenario

_Initial Note on Operational Costs in this ROI Scenario:_
_The following ROI calculation primarily uses cost figures derived from the detailed ROM estimates in [Costs of Building and Operating the Global Decentralized FDA (ROM Estimate)](#costs-of-building-and-operating-the-global-decentralized-fda-rom-estimate). This includes the core platform build and operational costs, as well as scenarios for broader initiative costs. This approach provides a more grounded basis for the ROI than previous high-level conceptual figures for a fully scaled global ecosystem._

- **Industry R&D Spend** (Baseline): [`{python} format_billions(GLOBAL_TRIAL_MARKET)`/year](#market-size-and-impact) globally (approx.).
- **Potential Savings**: 50% reduction implies [`{python} format_billions(DFDA_GROSS_SAVINGS)`/year saved](#gross-r-and-d-savings-from-dfda-implementation) if the entire industry migrated.
- **Platform Cost Scenarios (Derived from ROM Estimates):**
  - **Upfront Cost (Core Platform Build):** [~\`{python} format_millions(DFDA_ANNUAL_OPEX)`](#upfront-capital-expenditure-initial-build-illustrative-30-months) (representative figure from [Upfront (Capital) Expenditure](#upfront-capital-expenditure-initial-build-illustrative-30-months)).
  - **Annual Operational Cost Scenarios:**
    - **Scenario 1: Core Platform Only:** ~$11 - $26.5 Million / year (from [Annual Operational Costs](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month)). Let's use a midpoint of ~$19 Million/year for calculation.
    - **Scenario 2: Lean Ecosystem (Core Platform + Medium Broader Initiatives):**
      - Core Platform Ops (midpoint from [Annual Operational Costs](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month)): ~$19 Million/year
      - Medium Broader Initiative Annual Costs (from [Scenario-Based ROM Estimates](#scenario-based-rom-estimates-for-broader-initiative-costs)): ~$21 Million/year
      - **Total Lean Ecosystem Annual Cost:** ~$19M + ~$21M = **~\`{python} format_millions(DFDA_ANNUAL_OPEX)`/year** (or $0.04 Billion/year). This aligns with the cost basis for the ROI cited in the Executive Summary.
    - _(Other scenarios, such as including "Worst Case" broader initiative costs from [Scenario-Based ROM Estimates](#scenario-based-rom-estimates-for-broader-initiative-costs), could be considered for sensitivity analysis but would significantly increase annual costs.)_
- **Net Annual Savings** (assuming full adoption and [50% R and D cost reduction](#gross-r-and-d-savings-from-dfda-implementation)): `{python} format_billions(DFDA_GROSS_SAVINGS)`/year.

From a purely financial perspective, if the industry can move to such a platform and achieve these savings:

$$
\text{ROI} = \frac{\text{Net Annual Savings}}{\text{Annualized Platform Cost}}
$$

Let's calculate ROI based on the **Lean Ecosystem** scenario:

- Upfront Cost (Core Platform Build from [Upfront (Capital) Expenditure](#upfront-capital-expenditure-initial-build-illustrative-30-months)): `{python} format_millions(DFDA_ANNUAL_OPEX)`. Amortized over 5 years: $8 Million/year.
- Annual Operational Cost (Lean Ecosystem - Core Platform Ops from [Annual Operational Costs](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month) + Medium Broader Initiatives from [Scenario-Based ROM Estimates](#scenario-based-rom-estimates-for-broader-initiative-costs)): ~`{python} format_millions(DFDA_ANNUAL_OPEX)`/year.
- Total Annualized Cost: $8M (amortized upfront) + [`{python} format_millions(DFDA_ANNUAL_OPEX)` (annual ops)](#simplified-roi-scenario) = **\$48 Million/year** (or $0.048 Billion/year).

_This simplified calculation, based on a basic amortization of upfront costs, yields an exceptionally high ROI. However, a more rigorous Net Present Value (NPV) analysis, which properly discounts future costs and savings, is detailed in [Calculation Framework](#calculation-framework). The NPV analysis provides the final estimated ROI of approximately [**`{python} format_roi(ROI_TIER_1_CONSERVATIVE)`**](#final-roi-and-net-benefit), which is the figure cited throughout this document._

### Full Range ROI Sensitivity Analysis

To provide a comprehensive view, we can calculate the ROI across the full spectrum of cost possibilities by combining the Core Platform costs with the Broader Initiative scenarios from [Costs of Building and Operating the Global Decentralized FDA](#costs-of-building-and-operating-the-global-decentralized-fda-rom-estimate).

**Assumptions for Full Range ROI Calculation:**

- Net Annual Savings: [`{python} format_billions(DFDA_GROSS_SAVINGS)`/year](#gross-r-and-d-savings-from-dfda-implementation) (from 50% R&D cost reduction).
- Amortization Period for Upfront Costs: 5 years.

#### 1. Lowest Total Cost Scenario (Best Case Core Platform + Best Case Broader Initiatives)

- **Upfront Costs:**
  - Core Platform Build (Low end from [Upfront (Capital) Expenditure](#upfront-capital-expenditure-initial-build-illustrative-30-months)): [~\$37.5 Million](#upfront-capital-expenditure-initial-build-illustrative-30-months)
  - Broader Initiatives (Best Case Upfront from [Scenario-Based ROM Estimates](#scenario-based-rom-estimates-for-broader-initiative-costs)): [~\$4.5 Million](#scenario-based-rom-estimates-for-broader-initiative-costs)
  - _Total Lowest Upfront Cost:_ $37.5M + $4.5M = **\$42 Million**
  - _Amortized over 5 years:_ [\$42M](#full-range-roi-sensitivity-analysis-based-on-section-3-scenarios) / 5 = **\$8.4 Million/year**
- **Annual Operational Costs:**
  - Core Platform Operations (Low end from [Annual Operational Costs](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month)): [~\$11 Million/year](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month)
  - Broader Initiatives (Best Case Annual from [Scenario-Based ROM Estimates](#scenario-based-rom-estimates-for-broader-initiative-costs)): [~\$0 Million/year](#scenario-based-rom-estimates-for-broader-initiative-costs)
  - _Total Lowest Annual Operational Cost:_ **\$11 Million/year**
- **Total Lowest Annualized Cost:** [\$8.4M (amortized upfront)](#full-range-roi-sensitivity-analysis-based-on-section-3-scenarios) + [\$11M (annual ops)](#full-range-roi-sensitivity-analysis-based-on-section-3-scenarios) = **\$19.4 Million/year**
- **ROI (Lowest Cost Scenario):** [\`{python} format_billions(DFDA_GROSS_SAVINGS)`](#gross-r-and-d-savings-from-dfda-implementation) / [\$0.0194 Billion](#full-range-roi-sensitivity-analysis-based-on-section-3-scenarios) ≈ **2577:1**

#### 2. Highest Total Cost Scenario (Worst Case Core Platform + Worst Case Broader Initiatives)

- **Upfront Costs:**
  - Core Platform Build (High end from [Upfront (Capital) Expenditure](#upfront-capital-expenditure-initial-build-illustrative-30-months)): [~\$46 Million](#upfront-capital-expenditure-initial-build-illustrative-30-months)
  - Broader Initiatives (Worst Case Upfront from [Scenario-Based ROM Estimates](#scenario-based-rom-estimates-for-broader-initiative-costs)): [~\$2.231 Billion](#scenario-based-rom-estimates-for-broader-initiative-costs)
  - _Total Highest Upfront Cost:_ $46M + $2.231B = **~\$2.277 Billion**
  - _Amortized over 5 years:_ [\$2.277B](#full-range-roi-sensitivity-analysis-based-on-section-3-scenarios) / 5 = **~\$455.4 Million/year**
- **Annual Operational Costs:**
  - Core Platform Operations (High end from [Annual Operational Costs](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month)): [~\$26.5 Million/year](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month)
  - Broader Initiatives (Worst Case Annual from [Scenario-Based ROM Estimates](#scenario-based-rom-estimates-for-broader-initiative-costs)): [~\$271 Million/year](#scenario-based-rom-estimates-for-broader-initiative-costs)
  - _Total Highest Annual Operational Cost:_ $26.5M + $271M = **~\$297.5 Million/year**
- **Total Highest Annualized Cost:** [\$455.4M (amortized upfront)](#full-range-roi-sensitivity-analysis-based-on-section-3-scenarios) + [\$297.5M (annual ops)](#full-range-roi-sensitivity-analysis-based-on-section-3-scenarios) = **~\$752.9 Million/year**
- **ROI (Highest Cost Scenario):** [\`{python} format_billions(DFDA_GROSS_SAVINGS)`](#gross-r-and-d-savings-from-dfda-implementation) / [\$0.7529 Billion](#full-range-roi-sensitivity-analysis-based-on-section-3-scenarios) ≈ **66:1**

This full range sensitivity analysis demonstrates that the ROI for the dFDA initiative remains exceptionally positive. Even at the highest conceivable costs derived from the ['Costs of Building and Operating the Global Decentralized FDA ROM Estimate'](#costs-of-building-and-operating-the-global-decentralized-fda-rom-estimate) section, the financial return is substantial.

---
